Can chewing gum be another source of preanalytical variability in fasting outpatients?

Ricardas Stonys¹, Valdas Banys¹,², Dalius Vitkus¹,², Gabriel Lima-Oliveira³,⁴

¹ Center of Laboratory Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania
² Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
³ Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Italy
⁴ Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI), Montevideo, Uruguay

ARTICLE INFO

Corresponding author:
Gabriel Lima-Oliveira
Section of Clinical Biochemistry
Department of Neurosciences
Biomedicine and Movement Sciences
University of Verona
Italy
E-mail: dr.g.lima.oliveira@gmail.com

Key words:
blood specimen collection, diagnostic errors, fasting, postprandial period, reproducibility of results

ABSTRACT

Introduction

In the daily laboratory practice, there are patients coming to blood collection sites chewing sugar-free gum, considering it irrelevant to laboratory tests. The aim of this study was to evaluate whether a sugar-free chewing gum can interfere with laboratory tests.

Methods

We studied 22 healthy volunteers. After a 12-hour overnight fasting, the first blood sample was collected between 8:00 and 8:30 a.m. Then, immediately after the first venous blood collection, the subjects started chewing the gum (declared sugar-free) for 20 min. Subsequent venous blood samples were collected at 1, 2, and 4 hours after chewing the gum. Significant differences between samples were assessed by the Wilcoxon ranked-pairs test.

Results

Among all the results, statistically significant differences (p < 0.05) between basal and x hours after chewing
Can chewing gum be another source of preanalytical variability in fasting outpatients?

Ricardas Stonys, Valdas Banys, Dalius Vitkus, Gabriel Lima-Oliveira

INTRODUCTION

Chewing is essential during food consumption since it helps swallowing and food digestion. Moreover, Hirano et al. have shown that chewing is linked with cognitive functions (i.e., learning, memory and attention) [1]. Regarding the prolonged chewing consequent to chewing gum habit, it has some favorable outcomes such as: i) removal of food debris and plaque from teeth; ii) stimulation of saliva flow; and iii) reduction of gingivitis [2]. Moreover, chewing gum has been proven to stimulate the cephalic phase of gastric secretion on par with food chewing. The amount of acid output stimulated after 15 min of chewing the gum was very similar to the acid output after a cheeseburger meal [3]. It is well known that the hydrochloric acid secretion into the stomach is linked to:

1) extraction from blood plasma of Cl⁻, Na⁺, CO₂, and H₂O;
2) maintenance of blood electrolyte equilibrium through the release of HCO₃⁻ into the blood leaving the stomach (alkaline tide) [4].

Therefore, the fake feeding-induced gastric secretion due to chewing gum should be considered carefully when laboratory tests needing patient fasting are to be performed.

Currently, the management of patient preparation before laboratory testing requires attention since the evidence has shown that fasting time is required before blood sampling [5-7], except for lipid profile assessment [8, 9]. However, the GP 41, a standard for global application developed through the Clinical and Laboratory Standards Institute (CLSI) consensus process, recommends “no chewing gum, or other objects (e.g. thermometer) should be in the patient’s mouth at the time the specimen is collected” although no information is provided about allowance or denial regarding chewing gum habit before blood specimen collection [10]; whereas, a joint document from the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and Latin America Confederation of Clinical Biochemistry (COLABIOCLI) states that “chewing gum should not be used” without any scientific evidence that it could be a source of laboratory variability [11].

In the daily laboratory practice, there are patients coming to blood collection sites chewing sugar-free gum, considering it irrelevant with respect to fasting status. Moreover, laboratory professionals lack evidence to define patient preparation regarding this issue. The aim of this study was to evaluate whether chewing sugar-free gum can interfere with laboratory tests.

MATERIALS AND METHODS

A total of 22 healthy volunteers (13 women and 9 men; average age was 31 (22-52) years) were selected from the personnel of the Center of Laboratory Medicine of the Vilnius University Hospital Santaros Klinikos and included in the study. Informed consent was obtained from all study subjects according to the 2013 Declaration
of Helsinki and the protocol was approved by the Ethic Committee.

After a 12-hour overnight fast, the first blood sample was collected between 8:00 and 8:30 a.m. Then, immediately after the first venous blood collection, the subjects started chewing 2.8 g of sugar-free chewing gum (Orbit Spearmint, Wrigley company, Plymouth, USA) for 20 minutes. The composition of the chewing gum is declared in Table 1. Subsequent venous blood samples were collected at 1, 2, and 4 hours after chewing sugar-free gum.

| Nutritional composition of sugar-free chewing gum |
|-----------------------------------------------|
| Nutritional composition                      |
| overall weight (g)                           | 2.8 |
| KJ                                           | 17.8|
| Kcal                                         | 4.3 |
| total carbohydrates (g)                      | 1.8 |
| proteins (g)                                 | 0   |
| total lipids (g)                             | 0   |

According to the CLSI GP 41 and the EFLM-COLABIOCCLI recommendations [10, 11], all venous blood sampling procedures were carried out by a single phlebotomist. In order to eliminate possible blood distribution interferences, all volunteers were kept in an upright sitting position for 15 min [12-14]. Then, a vein was located on the forearm using a subcutaneous tissue transilluminator device (Venoscópio IV plus; Duan do Brasil, Brazil), in order to prevent venous stasis interference through tourniquet [15-18] and to avoid clenching [19].

All blood samples were collected directly into one 1.8 mL evacuated tube containing 3.2% sodium citrate 9N, one 3.5 mL evacuated tube containing gel separator and clot activator for serum samples, and one 4.0 mL evacuated tube containing K<sub>2</sub>EDTA (Vacumed®, FL Medical, Torreglia, Italy) using a 20 gauge needle in a closed evacuated system (FL Medical, Torreglia, Italy). To eliminate any possible interference due to either the contact phase or tissue factor, approximately 2 mL of blood were preliminarily collected in a discard tube without additives (Vacumed®, FL Medical, Torreglia, Italy). The blood collection procedure was appropriately standardized in each phase, as already reported [20, 21], particularly regarding the sample processing, centrifugation and serum/plasma separation.

All the samples were assayed in a single analytical run in the same instrument according to the manufacturer’s specifications and using proprietary reagents. The panel of tests that were performed and the instruments used by the Center of Laboratory Medicine of the Vilnius University Hospital Santaros Klinikos are shown in Table 2.

The instruments were calibrated against appropriate proprietary reference standard materials and verified with independent third-party control materials (Liquid Assayed Multiqual<sup>®</sup> Level 1 for routine biochemistry tests (Bio-Rad, California, USA) and Multichem IA Plus<sup>®</sup> Level 1 for immunochemistry assays (Technopath Clinical Diagnostics, Ballina, Ireland)) [22].

The evaluation of the within-run precision by the internal quality control of the instruments used in this study showed low coefficients of variation (Table 2).
Can chewing gum be another source of preanalytical variability in fasting outpatients?

Table 2  Results of within-run precision by the internal quality control used on the instruments

| Part I: Clinical chemistry |
|---------------------------|
| Instrument | Test | Method | IQC assigned value | CVa (%) |
| Arhitect ci8200, Abbott | Glc | enzymatic, Hexokinase / G-6-PDH, UV | 3.13 mmol/L | 1.2 |
| | Cortisol | CMIA | 127 nmol/L | 7.4 |
| | Ins | CMIA | 17.1 pmol/L | 6.7 |
| | C peptide | CMIA | 39.1 nmol/L | 4.6 |
| | CHOL | enzymatic, cholesterol oxidase / cholesterol esterase | 2.90 mmol/L | 0.5 |
| | HDL | accelerator selective detergent, cholesterol oxidase / cholesterol esterase | 0.74 mmol/L | 2.5 |
| | TG | enzymatic, glycerol phosphate oxidase | 0.91 mmol/L | 1.4 |
| | TP | biuret | 38.1 g/L | 0.5 |
| | Alb | bromocresol green, colorimetric | 0.36 mmol/L | 0.4 |
| | UA | enzymatic, uricase | 0.21 mol/L | 6.8 |
| | Urea | UV, urease | 2.46 mmol/L | 4.0 |
| | CREA | enzymatic | 0.08 mmol/L | 4.1 |
| | CRP | latex immunoturbidimetric | 8.10 nmol/L | 2.6 |
| | ALP | p-nitrophenyl phosphate | 34.2 U/L | 2.8 |
| | AMY-P | enzymatic, colorimetric | 23.3 U/L | 4.3 |
| | AMY | CNPG3 substrate | 45.4 U/L | 1.6 |
| Test | Method | Reference | Value   | Coefficient of Variation |
|------|--------|-----------|---------|-------------------------|
| AST  | IFCC, NADH, with P5P | 40.6 U/L | 7.3     |
| ALT  | IFCC, NADH, with P5P | 24.5 U/L | 1.2     |
| GGT  | L-Gamma-glutamyl-3-carboxy-4-nitroanilide substrate | 29.5 U/L | 3.2     |
| LD   | IFCC, UV lactate-pyruvate | 116 U/L | 0.6     |
| Lip  | quinone dye | 20.6 U/L | 8.2     |
| CK   | N-acetyl-L-cysteine, NAC | 83.5 U/L | 4.8     |
| TBIL | diazonium salt | 11.8 µmol/L | 1.0 |
| DBIL | diazo reaction | 5.82 µmol/L | 7.8 |
| Phos | UV, phosphomolybdate | 0.61 mmol/L | 0.3 |
| Ca   | arsenazo III, colorimetric | 1.54 mmol/L | 0.4 |
| Mg   | enzymatic, isocitrate dehydrogenase | 0.77 mmol/L | 4.9 |
| Fe   | ferene, colorimetric | 12.2 µmol/L | 4.0 |
| Na   | ion-selective electrode, indirect | 117 mmol/L | 0.9 |
| K    | ion-selective electrode, indirect | 2.59 mmol/L | 1.1 |
| Cl   | ion-selective electrode, indirect | 78.9 mmol/L | 1.0 |
| TSH  | CMIA | 0.048 µU/L | 11.0 |
| fT4  | CMIA | 11.2 pmol/L | 3.3 |

**Part II: Hematology**

| Instrument | Test | Method | Value   | Coefficient of Variation |
|------------|------|--------|---------|-------------------------|
| XN-1000, Sysmex | RBC | impedance | $4.50 \times 10^{12}$/L | 8.0 |
|      | Hct | calculated | 0.47 L/L | 0.3 |
|      | Hb  | photometric | 155 g/L | 0.7 |
|      | MCV | calculated | 88.5 fL | 0.1 |
Part III: Coagulation

| Test          | Method                                      | Value 1     | Value 2 |
|---------------|---------------------------------------------|-------------|---------|
| PT            | coagulometric, Owren                        | 14.7 s      | 6.5     |
| APTT          | coagulometric, silica                       | 35.5 s      | 7.7     |
| Fbg           | coagulometric, Clauss                       | 2.9 g/L     | 11.1    |
| PC            | chromogenic, Agkistrodon c. contortrix venom| 96 %        | 7.3     |
| PS            | latex immunoturbidimetric                   | 62 %        | 12.6    |

IQC – internal quality control; CVa – analytical coefficient of variation; Glc – glucose; Ins – insulin; CHOL – cholesterol; HDL – high density lipoprotein; TG – triglycerides; TP – total protein; Alb – albumin; UA – uric acid; CREA – creatinine; CRP – C reactive protein; ALP – alkaline phosphatase; AMY-P – pancreatic amylase; AMY – amylase; AST – aspartate aminotransferase; ALT – alanine aminotransferase; GGT – gamma glutamyl transferase; LD – lactate dehydrogenase; Lip – lipase; CK – creatine kinase; TBIL – total bilirubin; DBIL – direct bilirubin; Phos – phosphate; Ca – calcium; Mg – magnesium; Fe – iron; Na – sodium; K – potassium; Cl – chloride; TSH – thyroid stimulating hormone; fT4 – free thyroxin; RBC – red blood cells; Hct – haematocrit; Hb – haemoglobin; MCV – mean cell volume; RDW – red cell distribution width; WBC – white blood cells; Lympho – lymphocytes; Mono – monocytes; Neu – neutrophils; Eos – eosinophils; Baso – basophils; IG – immature granulocytes; Plt – platelets; PDW – platelet distribution width; MPV – mean platelet volume; PT – prothrombin time; APTT – activated partial thromboplastin time; Fbg – fibrinogen; PC – protein C; PS – protein S; UV – ultraviolet; CMIA – chemiluminescent microparticle immunoassay; NADPH - nicotinamide adenine dinucleotide phosphate; NAC – N-acetyl cysteine; IFCC – international federation of clinical chemistry and laboratory medicine.
For assessing the statistical differences between samples, the Wilcoxon ranked-pairs test was used in agreement with Simundic’s [23] recommendations regarding sample size (i.e. less than 30), with a licensed statistical software (GraphPad Prism® version 5.01, La Jolla, CA, USA). The level of statistical significance was set at \( p < 0.05 \).

Presently there is a lack of harmonization on the preanalytical methodology for evaluating a single source of laboratory variability (e.g., impact of chewing gum). Researchers use different statistical tools to estimate bias and clinical significance: (i) bland-Altman analysis [24]; (ii) percentage mean difference [25] – which represents the difference between baseline and treatment values divided by the treatment value – the method we chose; and iii) Passing-Bablok regression with 95% confidence intervals [26].

To calculate the percentage mean difference, we decided to use the following formula:

\[
\text{mean \% difference} = \frac{[X_h \text{ after chewing sugar-free gum} - \text{basal}] / X_h \text{ after chewing sugar-free gum}}{X_h \text{ after chewing sugar-free gum}} \times 100%.
\]

Using it we could avoid the possible “false positive source of variability” since it is more sensitive than:

\[
\text{mean \% difference} = \frac{[\text{basal} - X_h \text{ after chewing sugar-free gum}] / \text{basal}}{\text{basal}} \times 100%.
\]

In this way, only strong sources of preanalytical variability can be identified.

Finally, the mean % differences between blood samples taken 1, 2 and 4 hours after chewing sugar-free gum, were compared with the desirable specification for imprecision (DSI) derived from biologic variation [27]. We used DSI as criterium of acceptable level of interference by chewing gum in the laboratory tests; then interferograms were provided for each laboratory parameters with significant difference between h after chewing sugar-free gum and basal.

Briefly, in our study design, each volunteer was devised to be her/his own control (i.e. the results from 1, 2 and 4 hours after chewing sugar-free gum were compared with basal-results of the same individual). Indeed, this kind of study design – a case-crossover study – is most suitable for outcomes where the induction time is short [28], like our evaluation of impact of chewing gum on laboratory test results. In fact, in a case-crossover study, only cases showing discordant exposure status in the case/control window-of-time contribute to the effect and thus to the measure estimation. Because cases and controls are the same individuals, the problem of between-person confounders—that anyway exists with a control group—being constant for the characteristics, do not occur [29]. Therefore, our design minimizes the variability that could jeopardize the preanalytical evaluation.

RESULTS

The results of the laboratory tests are presented as median [interquartile range] in Table 3. Among all the results, statistically significant differences between basal and \( X_h \) after chewing sugar-free gum were observed for the following parameters: cortisol, insulin, C peptide, triglycerides, uric acid, urea, amylase, alanine aminotransferase, lipase, creatine kinase, total bilirubin, direct bilirubin, phosphate, iron, potassium, thyroid stimulating hormone, red blood cell count, hematocrit, hemoglobin, mean cell volume, red cell distribution width, white blood cell count, lymphocytes, neutrophils, and eosinophils; whereas, coagulation tests were not impacted by chewing sugar-free gum (Figure 1).
Can chewing gum be another source of preanalytical variability in fasting outpatients?

Legend follows on next page.
Legend of Figure 1:
A, cortisol; B, Ins – insulin; C, C-peptide; D, TG – triglycerides; E, Lip – lipase; F, CK – creatine kinase; G, urea; H, ALT – alanine aminotransferase; I, TBIL – total bilirubin; J, DBIL – direct bilirubin; K, UA – uric acid; L, MY – amylase; M, Phos – phosphate; N, K – potassium; O, TSH – thyroid stimulating hormone; P, RBC – red blood cells; Q, Hb – haemoglobin; R, Hct – haematocrit; S, WBC – white blood cells; T, Neu – neutrophils; U, Lympho – lymphocytes; and V, Eos – eosinophils

Hours after the chewing the gum (x-axis) are plotted against bias values (y-axis). Solid line – bias. Dashed lines - acceptable criteria based on desirable specification for imprecision (DSI) derived from biologic variation.

Table 3 Laboratory test results variation after chewing sugar-free gum

| Test   | Unit   | Basal       | 1h          | 2h          | 4h          |
|-------|--------|-------------|-------------|-------------|-------------|
| Glc   | mmol/L | 4.61 [4.30 - 4.78] | 4.60 [4.31 - 4.77] | 4.51 [4.43 - 4.84] | 4.49 [4.32 - 4.71] |
| Cortisol | nmol/L | 290 [219 - 383] | 212 [149 - 279] | 215 [183 - 290] | 235 [172 - 292] |
| Ins   | pmol/L | 41.0 [30.6 - 67.9] | 36.7 [24.9 - 51.8] | 34.0 [24.5 - 55.1] | 31.6 [22.0 - 42.9] |
| C peptide | nmol/L | 0.41 [0.36 - 0.62] | 0.38 [0.33 - 0.56] | 0.36 [0.30 - 0.53] | 0.33 [0.26 - 0.46] |
| CHOL  | mmol/L | 4.68 [4.34 - 5.58] | 5.59 [4.32 - 4.46] | 5.60 [4.24 - 5.48] | 4.68 [4.37 - 5.48] |
| HDL   | mmol/L | 1.59 [1.38 - 1.96] | 1.58 [1.35 - 1.92] | 1.59 [1.33 - 1.90] | 1.57 [1.32 - 1.88] |
| TG    | mmol/L | 0.68 [0.54 - 0.83] | 0.59 [0.48 - 0.87] | 0.58 [0.50 - 0.86] | 0.74 [0.57 - 0.88] |
| TP    | g/L    | 76.3 [71.8 - 77.9] | 75.4 [72.0 - 77.7] | 75.3 [71.8 - 78.1] | 75.5 [72.8 - 80.4] |
Can chewing gum be another source of preanalytical variability in fasting outpatients?

|          | g/L         | g/L         | g/L         | g/L         |
|----------|-------------|-------------|-------------|-------------|
| Alb      | 46.3 [44.5 - 48.0] | 46.5 [44.7 - 47.3] | 46.4 [43.6 - 49.8] | 46.5 [45.7 - 48.0] |
| UA       | 0.33 [0.25 - 0.39] | 0.35 [0.27 - 0.41] | 0.36 [0.27 - 0.42] | 0.36 [0.27 - 0.42] |
| Urea     | 4.68 [3.75 - 5.79] | 4.50 [3.70 - 5.64] | 4.30 [3.66 - 5.51] | 4.16 [3.68 - 5.46] |
| CREA     | 0.08 [0.06 - 0.09] | 0.08 [0.07 - 0.09] | 0.08 [0.07 - 0.09] | 0.08 [0.07 - 0.09] |
| CRP      | 4.76 [2.86 - 5.81] | 4.67 [2.76 - 6.19] | 4.86 [2.76 - 6.67] | 4.76 [2.86 - 6.19] |
| ALP      | 56 [48 - 66] | 57 [47 - 62] | 57 [49 - 62] | 57 [47 - 61] |
| AMY-P    | 27 [21 - 35] | 27 [21 - 30] | 27 [20 - 31] | 27 [21 - 31] |
| AMY      | 63 [55 - 80] | 59 [49 - 78] | 55 [45 - 78] | 51 [40 - 68] |
| AST      | 23 [17 - 29] | 22 [20 - 28] | 23 [19 - 29] | 22 [19 - 30] |
| ALT      | 28 [17 - 38] | 28 [16 - 37] | 25 [16 - 32] | 23 [15 - 30] |
| GGT      | 17 [10 - 22] | 17 [10 - 23] | 17 [10 - 24] | 17 [10 - 24] |
Can chewing gum be another source of preanalytical variability in fasting outpatients?

|     |     | 185 [161 - 200] | 187 [163 - 201] | 186 [160 - 203] | 186 [160 - 199] |
|-----|-----|----------------|----------------|----------------|----------------|
| LD  | U/L | 185 [161 - 200] | 187 [163 - 201] | 186 [160 - 203] | 186 [160 - 199] |
| Lip | U/L | 20 [17 - 23]     | 22 [16 - 22]    | 24 [18 - 26]    | 24 [18 - 27]    |
| CK  | U/L | 116 [71 - 130]   | 125 [79 - 145]  | 125 [78 - 146]  | 120 [80 - 138]  |
| TBIL| µmol/L | 11.1 [8.55 - 12.3] | 12.0 [8.38 - 13.7] | 12.0 [8.21 - 14.0] | 13.7 [10.6 - 16.2] |
| DBIL| µmol/L | 4.79 [3.59 - 5.64] | 4.79 [3.76 - 5.64] | 5.47 [4.10 - 6.16] | 6.17 [4.28 - 6.84] |
| Phos| mmol/L | 1.03 [0.94 - 1.23] | 1.00 [0.97 - 1.17] | 1.10 [1.00 - 1.21] | 1.20 [1.10 - 1.23] |
| Ca  | mmol/L | 2.43 [2.42 - 2.46] | 2.44 [2.40 - 2.47] | 2.44 [2.39 - 2.47] | 2.44 [2.37 - 2.48] |
| Mg  | mmol/L | 0.83 [0.79 - 0.86] | 0.83 [0.79 - 0.84] | 0.83 [0.79 - 0.84] | 0.83 [0.80 - 0.84] |
| Fe  | µmol/L | 18.1 [12.4 - 23.3] | 18.3 [12.2 - 23.1] | 18.3 [12.5 - 23.5] | 19.5 [14.7 - 23.3] |
| Na  | mmol/L | 140 [139 - 141]  | 140 [140 - 141]  | 140 [138 - 140]  | 141 [140 - 143]  |
| K   | mmol/L | 4.15 [3.91 - 4.22] | 4.40 [4.21 - 4.48] | 4.42 [4.20 - 4.40] | 4.00 [3.89 - 4.18] |
Ricardas Stonys, Valdas Banys, Dalius Vitkus, Gabriel Lima-Oliveira

Can chewing gum be another source of preanalytical variability in fasting outpatients?

|   |    | 106 [104 - 106] | 106 [104 - 107] | 106 [105 - 107] | 106 [104 - 107] |
|---|---|---|---|---|---|
| Cl | mmol/L | 106 [104 - 106] | 106 [104 - 107] | 106 [105 - 107] | 106 [104 - 107] |
| TSH | µIU/L | 1.41 [0.94 - 2.10] | 1.23 [0.84 - 1.81] | 1.15 [0.93 - 1.71] | 1.26 [0.95 - 1.85] |
| fT4 | pmol/L | 12.9 [11.7 - 13.5] | 12.9 [12.0 - 13.8] | 12.7 [11.7 - 13.6] | 12.7 [11.9 - 13.9] |

TSH

|   | µIU/L | 1.41 [0.94 - 2.10] | 1.23 [0.84 - 1.81] | 1.15 [0.93 - 1.71] | 1.26 [0.95 - 1.85] |
|---|---|---|---|---|---|
| TSH | µIU/L | 1.41 [0.94 - 2.10] | 1.23 [0.84 - 1.81] | 1.15 [0.93 - 1.71] | 1.26 [0.95 - 1.85] |
| fT4 | pmol/L | 12.9 [11.7 - 13.5] | 12.9 [12.0 - 13.8] | 12.7 [11.7 - 13.6] | 12.7 [11.9 - 13.9] |

Part II: Hematology

|   | 10¹²/L | 4.70 [4.33 - 5.20] | 4.55 [4.29 - 5.03] | 4.54 [4.20 - 5.02] | 4.40 [4.25 - 4.90] |
|---|---|---|---|---|---|
| RBC | 10¹²/L | 4.70 [4.33 - 5.20] | 4.55 [4.29 - 5.03] | 4.54 [4.20 - 5.02] | 4.40 [4.25 - 4.90] |
| Hct | L/L | 0.45 [0.40 - 0.46] | 0.41 [0.37 - 0.46] | 0.40 [0.38 - 0.45] | 0.40 [0.36 - 0.45] |
| Hb | g/L | 135 [126 - 149] | 132 [122 - 147] | 130 [122 - 148] | 130 [121 - 147] |
| MCV | fL | 90.8 [87.3 - 92.0] | 90.0 [86.8 - 91.4] | 89.1 [86.0 - 90.6] | 87.9 [85.0 - 90.1] |
| RDW | % | 44.0 [41.0 - 46.0] | 43.0 [40.2 - 45.9] | 42.1 [40.0 - 43.9] | 41.0 [39.3 - 44.2] |
| WBC | 10⁹/L | 5.20 [4.01 - 5.74] | 5.03 [4.18 - 5.72] | 5.36 [4.42 - 6.01] | 6.18 [5.11 - 6.98] |
| Lympho | 10⁹/L | 1.81 [1.40 - 1.93] | 1.62 [1.51 - 1.80] | 1.70 [1.52 - 2.03] | 1.98 [1.78 - 2.31] |
Can chewing gum be another source of preanalytical variability in fasting outpatients?

| Mono | $10^9/L$ | 0.41 [0.28 - 0.54] | 0.41 [0.29 - 0.50] | 0.38 [0.29 - 0.47] | 0.45 [0.31 - 0.53] |
|------|----------|---------------------|---------------------|---------------------|---------------------|
| Neu  | $10^9/L$ | 2.64 [1.98 - 3.10] | 2.73 [2.20 - 3.32] | 2.96 [2.44 - 3.41] | 3.42 [2.63 - 4.10] |
| Eos  | $10^9/L$ | 0.10 [0.06 - 0.14] | 0.07 [0.05 - 0.12] | 0.07 [0.05 - 0.10] | 0.07 [0.04 - 0.10] |
| Baso | $10^9/L$ | 0.04 [0.02 - 0.04] | 0.04 [0.02 - 0.04] | 0.04 [0.02 - 0.04] | 0.04 [0.03 - 0.04] |
| IG   | $10^9/L$ | 0.01 [0.00 - 0.01] | 0.01 [0.01 - 0.01] | 0.01 [0.00 - 0.02] | 0.01 [0.01 - 0.02] |
| Plt  | $10^9/L$ | 228 [204 - 269] | 226 [204 - 268] | 225 [204 - 267] | 229 [206 - 269] |
| PDW  | %       | 11.2 [10.0 - 12.0] | 11.5 [9.74 - 12.1] | 11.7 [9.98 - 12.4] | 11.4 [10.0 - 12.1] |
| MPV  | fL      | 10.0 [9.28 - 10.3] | 10.0 [9.35 - 10.2] | 10.1 [9.50 - 10.1] | 10.1 [9.51 - 10.2] |

**Part III: Coagulation**

| PT   | s       | 13.0 [12.6 - 13.2] | 13.0 [12.7 - 13.3] | 13.1 [12.8 - 13.4] | 13.1 [12.7 - 13.3] |
|------|---------|---------------------|---------------------|---------------------|---------------------|
| APTT | s       | 33.1 [32.2 - 36.0] | 33.2 [32.1 - 35.9] | 33.0 [31.6 - 36.5] | 33.1 [32.0 - 35.2] |
Can chewing gum be another source of preanalytical variability in fasting outpatients?

|    |    |    |    |    |
|----|----|----|----|----|
| Fbg | g/L | 2.94 [2.53 - 3.12] | 2.88 [2.50 - 3.15] | 2.89 [2.41 - 3.22] | 2.89 [2.42 - 3.16] |
| PC  | % activity | 102 [89.3 - 120] | 100 [89.7 - 119] | 100 [89.9 - 119] | 101 [90.3 - 117] |
| PS  | % activity | 88.3 [75.5 - 111] | 87.8 [75.2 - 111] | 88.2 [76.2 - 112] | 88.7 [76.1 - 111] |

Results are presented as median [interquartile range]. Statistically significant differences (P < 0.05) are presented in bold.

Glc – glucose; Ins – insulin; CHOL – cholesterol; HDL – high density lipoprotein; TG – triglycerides; TP – total protein; Alb – albumin; UA – uric acid; CREA – creatinine; CRP – C reactive protein; ALP – alkaline phosphatase; AMY-P – pancreatic amylase; AMY – amylase; AST – aspartate aminotransferase; ALT – alanine aminotransferase; GGT – gamma glutamyl transferase; LD – lactate dehydrogenase; Lip – lipase; CK – creatine kinase; TBL – total bilirubin; DBIL – direct bilirubin; Phos – phosphate; Ca – calcium; Mg – magnesium; Fe – iron; Na – sodium; K – potassium; Cl – chloride; TSH – thyroid stimulating hormone; fT4 – free thyroxin; Hct – haematocrit; Hb – haemoglobin; MCV – mean cell volume; RDW – red cell distribution width; WBC – white blood cells; Lympho – lymphocytes; Mono – monocytes; Neu – neutrophils; Eos – eosinophils; Baso – basophils; IG – immature granulocytes; Plt – platelets; MPV – mean platelet volume; PT – prothrombin time; APTT – activated partial thromboplastin time; Fbg – fibrinogen; PC – protein C; PS – protein S.

DISCUSSION

Our primary hypothesis was that chewing gum – even sugar free – could impact the glucose metabolism. However, the results of glucose, cortisol, insulin and C peptide levels properly evidenced that chewing gum lacks influence on glucose results (Table 3); the variability observed in cortisol, insulin and C peptide (Table 3, Figure 1a, 1b, 1c) could mirror cortisol circadian cycle [30] (since the first blood collection was at 8 am), and life cycle of these hormones [31]. Studies have shown that the insulin half-life varies between 4.3 and 9.8 min, whereas for C peptide the half-life could vary between 11.1 and 33.5 min [32-35]. Therefore, our insulin and C peptide results could mirror the prolonged fasting.

The chewing gum producer declares the following chemical constituents of the product on the pack label: a) sweeteners: E967 – xylitol, E421 – aspartame, E422 – sorbitol, E951 – acesulfame potassium, and E955 – sucralose; b) moisture additive: E422 – glycerol; c) thickener: E414 – gum Arabic; d) emulsifier: soy lecithin; e) food colouring: E171 – titanium dioxide; f) filler: E903 – carnauba wax; g) antioxidant: E320 – butylated hydroxyanisole. However, the chewing gum producer do not specify the quantities of mentioned constituents, furthermore, they do not specify the base of the gum (i.e., it is not declared on the gum package). Probably it is a mixture of resins, elastomers, fillers, and plasticizers [2].

Regarding lipids profile, total cholesterol and HDL cholesterol were not affected neither by prolonged fasting time [8] nor chewing gum (Table 3). However, the decrease in triglycerides one and two hours after chewing gum can mirror the gluconeogenesis and beta oxidation process, since volunteers had fasted for 13 and...
14 hours prior to blood collections, respectively. However, four hours after chewing gum the triglycerides concentration increased and returned almost up to the basal levels (Table 3, Figure 1d). Since glycerol is the moisture additive declared by the chewing gum producer (Table 1), it could be absorbed and provide positive bias in our enzymatic, glycerol phosphate oxidase method for triglyceride test. Moreover, the methodology of quinone dye is used on Architect to determine lipase activity. Briefly, lipase acts on a natural substrate, 1,2-diglyceride, to liberate 2-monoglyceride. This is hydrolyzed by monoglyceride lipase into glycerol and free fatty acid. Glycerol kinase acts on glycerol to form glycerol-3-phosphate which is in turn acted on by glycerol-3-phosphate oxidase to generate hydrogen peroxide. Peroxidase converts the hydrogen peroxide, 4-aminooantipyrine, and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine (TOOS) into a quinone dye. Thus, the rate of formation of the dye is measured as an increase in absorbance at 548 nm and is proportional to the lipase activity in the sample. Therefore, the glycerol from sugar-free chewing gum could potentially jeopardize lipase results (Table 3, Figure 1e).

The oxidation of NADPH by the radical of butylated hydroxyanisole (BHA, present in the chewing gum) was previously demonstrated [36, 37]. The short decrypts of the laboratory methods below could explain the variability observed in CK, urea, and ALT (Table 3, Figure 1f, 1g, 1h).

- CK: in N-acetyl-L-cysteine (NAC) methodology, the creatine kinase, present in the sample, catalyzes the transfer of a high energy phosphate group from creatine phosphate to ADP. The ATP produced in this reaction is subsequently used to phosphorylate glucose to produce glucose-6-phosphate (G-6-P) in the presence of hexokinase. G-6-P is then oxidized by glucose-6-phosphate dehydrogenase (G-6-PDH) with the concomitant reduction of nicotinamide adenine dinucleotide phosphate (NADP) to nicotinamide adenine dinucleotide phosphate reduced (NADPH). The rate of formation of NADPH is monitored at 340 nm and is proportional to the activity of CK in the sample. These reactions occur in the presence of N-acetyl-L-cysteine (NAC) which is present as an enzyme reactivator;

- Urea: in urease methodology, two moles of NADH are oxidized for each mole of urea present. The initial rate of decrease in absorbance at 340 nm is proportional to the urea concentration in the sample;

- ALT: in IFCC methodology, the pyruvate in the presence of NADH and lactate dehydrogenase is reduced to L-lactate. In this reaction NADH is oxidized to NAD. The reaction is monitored by measuring the rate of decrease in absorbance at 340 nm due to the oxidation of NADH to NAD.

Moreover, Vandghanooni et al. experimentally demonstrated that slight concentration of butylated hydroxyanisole – lower than expected from human exposure to antioxidants in food products, i.e. chewing gum – inhibits the growth rate of cells by inducing apoptosis via chromatin and DNA fragmentation [38]. Furthermore, the xylitol in the sugar-free chewing gum could be responsible for the increase observed in bilirubin, and uric acid [39, 40], and decrease in amylase [41] (Table 3, Figure 1i, 1j, 1k, 1l).

Similar results on phosphate, potassium and TSH (Table 3, Figure 1m, 1n, 1o) were demonstrated by Bajaña et al. [5] on volunteers after breakfast. Therefore, a question remains partially unanswered “Is the chewing gum able to activate digestive pathway?”. Regarding Smith et al. [4] chewing gum is, at least partially, able to stimulate the initial phases of gastric secretion that involve essentially water and ions’ movements. Our results seem to support the relative effect of haemoconcentration as deduced by red blood cell count, haemoglobin and
hematocrit decrease, an effect that appears reversible with time according to the physiological process of digestion (Table 3, Figure 1p, 1q, 1r).

Moreover, fake feeding-induced gastric secretion due to chewing gum is probably responsible for the white blood cell count and neutrophils increase, with lymphocytes and eosinophils decrease observed in our study (Table 3, Figure 1s, 1t, 1u, 1v) as reported by Koscielniak et al. after a normal meal [42]. On the contrary the sugar-free chewing gum does not have impact on routine coagulation tests (Table 3).

In conclusion, based on the variability evidenced above, we recommend instructing the patients to avoid the use of chewing gum before blood collection for laboratory tests.

Acknowledgments

Our sincere thanks to Prof. Algirdas Utkus, PhD, Dean of the Faculty of Medicine at the Vilnius University, Lithuania for inviting GLO from University of Verona for this research period at the Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine. Our sincere thanks to the general practice nurse Vida Dovydenaite who performed all blood collections. Our special thanks to the laboratory professionals Dalia Kazekeviuciute, Dovile Petronvte, and Laima Gogeliene for performing the laboratory tests on hematology, coagulation and clinical chemistry, respectively. Our gratitude to Riccardo Fiore F.L. Medical (Torreglia, Italy) who partially supported the project ADR 2451/15.

REFERENCES

1. Hirano Y, Onozuka M. Chewing and attention: a positive effect on sustained attention. Biomed Res Int 2015;2015: 367026.

2. Imfeld T. Chewing gum--facts and fiction: a review of gum-chewing and oral health. Crit Rev Oral Biol Med 1999;10: 405-19.

3. Helman CA. Chewing gum is as effective as food in stimulating cephalic phase gastric secretion. Am J Gastroenterol 1988;83:640-2.

4. Smith ME, Morton DG. The Digestive System: Systems of the Body Series. UK: Elsevier Health Sciences; 2011.

5. Bajaña W, Aranda E, Arredondo ME, Brennan-Bourdon LM, Campelo MD, Espinoza E, Flores S, Ochoa P, Vega V, Varela B, Lima-Oliveira G. Impact of an Andean breakfast on biochemistry and immunochemistry laboratory tests: an evaluation on behalf COLABIOCLI WG-PRE-LATAM. Biochem Med (Zagreb) 2019;19:020702.

6. Guidi GC, Simundic AM, Salvagno GL, Aquino JL, Lima-Oliveira G. To avoid fasting time, more risk than benefits. Clin Chem Lab Med 2015;53:e261-4.

7. Arredondo ME, Aranda E, Astorga R, Brennan-Bourdon LM, Campelo MD, Flores S, Medel C, Manriquez I, Ochoa P, Varela B, Salinas CV, Lima-Oliveira G. Breakfast can affect Routine Hematology and Coagulation Laboratory Testing: An Evaluation on Behalf of COLABIOCLI WG-PRE-LATAM. TH Open 2019;3:e367-e76.

8. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Boren J, Chapman MJ, Cobbett C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, European Atherosclerosis S, the European Federation of Clinical C, Laboratory Medicine Joint Consensus I. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 2016;62:930-46.

9. Lima-Oliveira G, Valentim CD, Guidi GC. Lipid profile, changes in laboratory prescriptions are necessary. J Clin Lipidol 2017;11:768-9.

10. Clinical Laboratory Standards Institute. Procedures for collection of diagnostic blood specimens by venipuncture. CLSI GP41. Wayne, PA.: Clinical Laboratory Standards Institute.

11. Simundic AM, Bolenius K, Cadamuro J, Church S, Cornes MP, van Dongen-Lases EC, Eker P, Erdeljanovic T, Grankvist K, Guimaraes JT, Hoke R, Ibarz M, Ivanov A, Kovalevskaya S, Kristensen GBB, Lima-Oliveira G, Lippi G, von Meyer A, Nybo M, Salle B, Seippel C, Sunarac Z, Vemeersch P. Joint EFLM-COLABIOCLI Recommendation for venous blood sampling. Clin Chem Lab Med 2018;56: 2015-38.
12. Lippi G, Salvagno GL, Lima-Oliveira G, Brocco G, Danese E, Guidi GC. Postural change during venous blood collection is a major source of bias in clinical chemistry testing. Clin Chim Acta 2015;440:164-8.

13. Lippi G, Salvagno GL, Lima-Oliveira G, Danese E, Favaloro EJ, Guidi GC. Influence of posture on routine hemostasis testing. Blood Coagul Fibrinolysis 2015;26:716-9.

14. Lima-Oliveira G, Guidi GC, Salvagno GL, Danese E, Montagnana M, Lippi G. Patient posture for blood collection by venipuncture: recall for standardization after 28 years. Rev Bras Hematol Hemoter 2017;39:127-32.

15. Lima-Oliveira G, Lippi G, Salvagno GL, Montagnana M, Manguera CL, Sumita NM, Picheth G, Guidi GC, Scartezini M. New ways to deal with known preanalytical issues: use of transilluminator instead of tourniquet for easing vein access and eliminating stasis on clinical biochemistry. Biochem Med (Zagreb) 2011;21:152-9.

16. Lima-Oliveira G, Lippi G, Salvagno GL, Gaino S, Poli G, Gelati M, Picheth G, Guidi GC. Venous stasis and whole blood platelet aggregometry: a question of data reliability and patient safety. Blood Coagul Fibrinolysis 2015;26:665-8.

17. Lima-Oliveira G, Lippi G, Salvagno GL, Montagnana M, Scartezini M, Guidi GC, Picheth G. Transillumination: a new tool to eliminate the impact of venous stasis during the procedure for the collection of diagnostic blood specimens for routine haematological testing. Int J Lab Hematol 2011;33:457-62.

18. Lima-Oliveira G, Salvagno GL, Lippi G, Montagnana M, Scartezini M, Picheth G, Guidi GC. Elimination of the venous stasis error for routine coagulation testing by transillumination. Clin Chim Acta 2011;412:1482-4.

19. Lima-Oliveira G, Guidi GC, Salvagno GL, Brocco G, Danese E, Lippi G. Estimation of the imprecision on clinical chemistry testing due to fist clenching and maintenance during venipuncture. Clin Biochem 2016;49:1364-7.

20. Lima-Oliveira G, Salvagno GL, Lippi G, Gelati M, Montagnana M, Danese E, Picheth G, Guidi GC. Influence of a regular, standardized meal on clinical chemistry analytes. Ann Lab Med 2012;32:250-6.

21. Lima-Oliveira G, Salvagno GL, Lippi G, Danese E, Gelati M, Montagnana M, Picheth G, Guidi GC. Could light meal jeopardize laboratory coagulation tests? Biochem Med (Zagreb) 2014;24:343-9.

22. Lima-Oliveira G, Lippi G, Salvagno G, Brocco G, Guidi GC. In vitro diagnostic company recalls and medical laboratory practices: an Italian case. Biochem Med (Zagreb) 2015;25:273-8.

23. Simundic AM. Practical recommendations for statistical analysis and data presentation in Biochemia Medica journal. Biochem Med (Zagreb) 2012;22:15-23.

24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.

25. Ialongo C, Bernardini S. Preanalytical investigations of phlebotomy: methodological aspects, pitfalls and recommendations. Biochem Med (Zagreb) 2017;27:177-91.

26. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983;21:709-20.

27. Westgard J. Desirable Biological Variation Database Specifications http://www.westgard.com/biodatabase1.htm 2014 [Accessed June 12th 2019].

28. Nazari SSH, Mansournia MA. Case-crossover and case-time-control studies: concepts, design, and analysis. J Biostat Epidemiol 2015;1:59-69.

29. Jensen AK, Gerds TA, Weeke P, Torp-Pedersen C, Andersen PK. On the validity of the case-time-control design for autocorrelated exposure histories. Epidemiology 2014;25:110-3.

30. Rose AJ, Herzig S. Metabolic control through glucocorticoid hormones: an update. Mol Cell Endocrinol 2013;380:65-78.

31. Hoekstra JB, van Rijn HJ, Erkelens DW, Thijsse MH. C-peptide. Diabetes Care 1982;5:438-46.

32. Faber OK, Hagen C, Binder C, Markussen J, Naithani VK, Blix PM, Kuzuya H, Horwitz DL, Rubenstein AH, Rossing N. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest 1978;62:197-203.

33. Kuzuya T, Matsuda A. Disappearance rate of endogenous human C-peptide from blood. Diabetologia 1976;12:519-21.

34. Sonksen PH, Tompkins CV, Srivastava MC, Nabarro JD. A comparative study on the metabolism of human insulin and porcine proinsulin in man. Clin Sci Mol Med 1973;45:633-54.

35. Starr JJ, Rubenstein AH. Metabolism of endogenous human C-peptide from blood. Diabetesologia 1976;12:519-21.

36. Castor LR, Locatelli KA, Ximenes VF. Pro-oxidant activity of apocynin radical. Free Radic Biol Med 2010;48:1636-43.

37. Babu S, Uppu S, Claville MO, Uppu RM. Prooxidant actions of bisphenol A (BPA) phenoxyl radicals: implications to BPA-related oxidative stress and toxicity. Toxicol Mech Methods 2013;23:273-80.

38. Vandghanoooni S, Forouharmehr A, Eskandani M, Barzegari A, Kafti V, Kashanian S, Ezzati Nazhad Dolatabadi J. Cytotoxicity and DNA fragmentation properties
of butylated hydroxyanisole. DNA Cell Biol 2013;32: 98-103.

39. Korttila K, Mattila MA. Increased serum concentrations of lactic, pyruvic and uric acid and bilirubin after postoperative xylitol infusion. Acta Anaesthesiol Scand 1979;23:273-7.

40. Schumer W. Adverse effects of xylitol in parenteral alimentation. Metabolism 1971;20:345-7.

41. Chukwuma CI, Islam MS. Effects of xylitol on carbohydrate digesting enzymes activity, intestinal glucose absorption and muscle glucose uptake: a multi-mode study. Food Funct 2015;6:955-62.

42. Koscielniak BK, Charchut A, Wojcik M, Sztefko K, Tomaski PJ. Impact of Fasting on Complete Blood Count Assayed in Capillary Blood Samples. Lab Med 2017; 48: 357-61.